Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other Classes

Hepatitis C virus (HCV) entry inhibitors (EIs) act synergistically with drugs targeting other stages of the HCV lifecycle. The origin of this synergy remains unknown. Here, we argue that the synergy may arise from the complementary activities of the drugs across cell subpopulations expressing differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Padmanabhan, P, Dixit, NM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562160/
https://www.ncbi.nlm.nih.gov/pubmed/26380153
http://dx.doi.org/10.1002/psp4.12005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562160/
https://www.ncbi.nlm.nih.gov/pubmed/26380153
http://dx.doi.org/10.1002/psp4.12005

Ejemplares similares